This study is testing if a drug called apixaban works better than aspirin for preventing strokes or death in people who had a recent brain bleed, known as intracerebral hemorrhage (ICH), and have a heart condition called atrial fibrillation (AF). AF is when the heart beats irregularly. Apixaban and aspirin are both blood thinners, which help prevent clots. The study will include 700 people, last up to 3.5 years, and involve at least 12 months of tracking outcomes, such as strokes or changes in daily activities measured by the modified Rankin Scale. Participants must be at least 18 years old, have had an ICH confirmed by a brain scan, and be able to join within 14 to 180 days after the ICH. Women who can have children must use effective birth control. Some conditions might prevent participation, like certain blood disorders, severe liver problems, or allergies to the study drugs.

• Participation could last between 12 to 36 months.
• 700 participants needed over 3.5 years.
• Apixaban and aspirin are being compared for safety and effectiveness.